We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...